- Home
- KTTA vs GIXI Comparison
KTTA vs GIXI Comparison
Compare KTTA & GIXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KTTA | GIXI |
|---|---|---|
| Founded | 2020 | N/A |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.1M | 14.6M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | KTTA | GIXI |
|---|---|---|
| Price | $0.52 | $5.59 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 214.9K | 29.3K |
| Earning Date | 05-14-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.07 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $486,559.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3130.37 | N/A |
| 52 Week Low | $0.28 | $4.92 |
| 52 Week High | $2.06 | $6.25 |
Technical Indicators
Market Signals| Indicator | KTTA | GIXI |
|---|---|---|
| Relative Strength Index (RSI) | 47.80 | 43.27 |
| Support Level | $0.48 | $4.92 |
| Resistance Level | $0.52 | $5.81 |
| Average True Range (ATR) | 0.04 | 0.51 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 34.21 | 53.43 |
Price Performance
Historical ComparisonAbout KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.